Beyond Checkpoints: Next-Gen Therapeutics for Solid Tumors

Despite the clinical and commercial success of immune checkpoint inhibitors like Keytruda and Opdivo, significant gaps remain, with only a fraction of patients achieving durable remissions. Revisit our on-demand webinar to hear an insightful discussion exploring the challenges and opportunities in the development of emerging therapeutic modalities aimed at addressing solid tumors in the post-PD1 era.

Moderated by Joel Sandler, PhD, Associate Partner at Ipsos Healthcare Advisory, this webinar proudly features industry leaders representing novel approaches including cell therapies, mRNA, RLTs, and next-generation chemotherapy, each achieving measurable and potentially replicable success across different tumor types and patient populations. Our discussion focuses on respective value propositions and positioning implications for each within the evolving competitive landscape. Don’t miss out on hearing expert insights about the future of oncology therapeutics.

Panelists:

• Joel Sandler, (moderator), Associate Partner; Ipsos Healthcare Advisory Services
• Geoff Towle, Vice President & Senior General Manager, Novartis; radioligand therapy
• Kai Blau, Business Director, NUP-CTx; next-generation chemotherapy
• Mark Frohlich, CEO, Indapta Therapeutics; NK cell therapy
• Randy Hyer, CEO, Merlin Biotech; mRNA therapy
• Reagan Jarvis, CEO, Anocca; TCR-T cell therapy